ERBB2 and breast cancer: This pathology is called “triple negative” due to the absence or very low expression of hormone receptors (for estrogen and for progesterone) by tumor cells, associated with a lack of amplification of the HER2 gene (ERBB2), all three biomarkers being the cornerstones of breast cancer therapy.